close
Add to watchlist
Warner Chilcott Ltd (WCRX)
Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women's healthcare and dermatology segments primarily in the United States. The company offers various women healthcare products, including LOESTRIN 24 FE and FEMCON FE as oral contraceptives; FEMHRT 1/5 and .5/2.5 for oral treatment of moderate to severe vasomotor symptoms and urogenital symptoms associated with menopause; and ESTRACE cream to treat vaginal and vulvar atrophy. It also offers various dermatology products, such as TACLONEX and DOVONEX for the topical treatment of psoriasis; and DORYX, an oral adjunctive therapy for severe acne. In addition, its products under development include WC3016 and WC3026, the Phase III clinical trial completed products for low-dose oral contraceptive; WC2055, a Phase II clinical trials completed product for the treatment of acne; WC3018, a Phase II clinical trials product for the treatment of acne and other inflammatory skin conditions; LEO 80-185 for psoriasis of the scalp; and LEO 80-190, a Phase III clinical trial product for the treatment of psoriasis. Further, the company's products under development comprise TD1414, a Phase II clinical trial product for skin infections; WC3027 for the treatment of inflammatory skin conditions; WC3035 for the treatment of acne and rosacea; and WC3036 and WC3043 for the treatment of erectile dysfunction. Warner Chilcott's principal customers include wholesale pharmaceutical distributors, and retail drug and grocery store chains. It has license and supply agreement with LEO Pharma A/S. The company was founded in 1968 and is headquartered in Rockaway, New Jersey.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 16.94 |
| Volume | (mio) 1.83 |
| Volume Avg | (mio) 2.13 |
| 52 Week High | 25.92 |
| 52 Week Low | 12.90 |
| PE | 25.43 |
| PE (group average) | N/A |
| EPS Year | 0.67 |
| EPS change Q/Q | 1000% |
| EPS change Q/Q Yr ago | -42.86% |
| EPS change Q/Q next Q est | 1000% |
| EPS change Y/Y | 176.92% |
| REV change Q/Q | 8.94% |
| REV change Q/Q Yr ago | -0.63% |
| EPS next Q est | 0.91 |
| EPS next Y est | 3.84 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |